

Summary of Financial Operations

Fiscal Year 2021 – Period 2 7/1/2020 to 8/31/2020

Overall Commentary for August

The COVID recovery plan and it's focus on volume recovery continues to yield results.

- For both ECH and SVMD the volumes exceeded the volume forecasts.
- Overall gross charges, a surrogate for volume, was exceeded the forecast by 30% in the month of August (Net Patient Revenue exceeded forecast by 27%)
- Operating Expenses were \$9.7M or 12% greater than budget and driven by the increased volumes
- Operating Margin favorable variance in comparison to the budget is \$8.2M. However, month-over-month performance was unfavorable due to a slight deterioration in payor mix, significant increase in supply expenses due to the capture of prior month expenses.
- Year-over-year operating margin is unfavorable by \$6.5M
- Continued focus on managing variable expenses and monitoring changes to payor mix will be critical to ensure the organization returns to consistent strong operating performance



Consolidated Statement of Operations (\$000s)

Period ending 08/31/2020

Period 2	Period 2	Period 2	Variance			YTD	YTD	YTD	Variance	
FY 2020	FY 2021	Budget 2021	Fav (Unfav)	Var%	\$000s	FY 2020	FY 2021	Budget 2021	Fav (Unfav)	Var%
					OPERATING REVENUE					_
317,087	339,121	260,556	78,565	30.2%	Gross Revenue	631,150	672,350	515,359	156,990	30.5%
(233,586)	(253,449)	(192,904)	(60,545)	(31.4%)	Deductions	(462,141)	(500,809)	(381,588)	(119,221)	(31.2%)
83,501	85,672	67,652	18,020	26.6%	Net Patient Revenue	169,009	171,540	133,771	37,769	28.2%
3,821	4,331	4,429	(98)	(2.2%)	Other Operating Revenue	7,931	8,998	8,810	188	2.1%
87,322	90,003	72,081	17,922	24.9%	Total Operating Revenue	176,940	180,538	142,581	37,957	26.6%
					OPERATING EXPENSE					
46,023	47,739	43,540	(4,198)	(9.6%)	Salaries & Wages	91,104	94,170	86,871	(7,298)	(8.4%)
13,122	16,893	10,692	(6,202)	(58.0%)	Supplies	26,433	29,713	21,175	(8,539)	(40.3%)
13,814	14,366	14,481	115	0.8%	Fees & Purchased Services	27,153	27,284	29,042	1,758	6.1%
3,595	3,596	4,213	617	14.6%	Other Operating Expense	6,940	7,179	7,726	548	7.1%
534	1,431	926	(505)	(54.5%)	Interest	1,065	2,859	1,848	(1,011)	(54.7%)
4,426	5,328	5,804	476	8.2%	Depreciation	8,991	10,559	11,615	1,056	9.1%
81,514	89,352	79,655	(9,697)	(12.2%)	Total Operating Expense	161,686	171,763	158,278	(13,486)	(8.5%)
5,808	651	(7,574)	8,225	(108.6%)	Net Operating Margin	15,254	8,775	(15,696)	24,471	(155.9%)
3,927	28,642	1,499	27,143	1810.9%	Non Operating Income	3,538	56,360	4,502	51,859	1152.0%
9,735	29,293	(6,075)	35,368	(582.2%)	Net Margin	18,792	65,135	(11,195)	76,330	(681.8%)
12.3%	8.2%	-1.2%	9.4%		EBIDA	14.3%	12.3%	-1.6%	13.9%	
6.7%	0.7%	-10.5%	11.2%		Operating Margin	8.6%	4.9%	-11.0%	15.9%	
11.1%	32.5%	-8.4%	41.0%		Net Margin	10.6%	36.1%	-7.9%	43.9%	





Dashboard - as of August 31, 2020

	Month				ĺ		YTD			
	PY	CY	Bud/Target	Variance	Ì	PY	CY	Bud/Target	Variance	
				CY vs Bud					CY vs Bud	
Consolidated Financial Perf.										
Total Operating Revenue	87,322	90,003	72,081	17,922		176,940	180,538	142,581	37,957	
Operating Expenses	81,514	89,352	79,655	(9,697)		161,686	171,763	158,278	(13,486	
Operating Margin \$	5,808	651	(7,574)	8,225		15,254	8,775	(15,696)	24,471	
Operating Margin %	6.7%	0.7%	(10.5%)	11.2%		8.6%	4.9%	(11.0%)	15.9%	
EBIDA \$	10,768	7,410	(844)	8,254		25,310	22,193	(2,233)	24,426	
EBIDA %	12.3%	8.2%	(1.2%)	9.4%		14.3%	12.3%	(1.6%)	13.99	
Hospital Volume										
Licensed Beds	443	454	454	-		443	454	454	-	
ADC	219	241	190	51		227	232	187	45	
Utilization MV	60%	62%	49%	13.2%	I	61%	60%	48%	11.69	
Utilization LG	28%	33%	26%	7.1%		30%	32%	26%	6.29	
Utilization Combined	49%	53%	42%	11.3%		51%	51%	41%	9.99	
Adjusted Discharges	3,338	2,996	2,471	525		6,439	5,841	4,890	951	
Total Discharges (Excl NNB)	1,692	1,619	1,331	288		3,378	3,093	2,633	460	
Total Discharges	2,073	2,005	1,660	345		4,098	3,819		532	
Inpatient Cases	, ,	,	,			,	-,-	-, -		
MS Discharges	1,153	1,042	820	222		2,344	2,014	1,621	393	
Deliveries	401	414		67		754	783		92	
BHS	98	114	120	(6)		193	201		(33	
Rehab	40	49		5		87	95		9	
Outpatient Cases	13,315	15,254	9,910	5,344	1	25,692	30,149	19,616	10,533	
ED ED	4,135	3,118		720		8,288	6,291	4,695	1,596	
Procedural Cases	1,133	5,110	2,550	-	•	0,200	0,231	.,055	-	
OP Surg	522	500	327	173		999	1,014	651	363	
Endo	235	228		94		432	485		221	
Interventional	191	160		68		345	346		169	
All Other	8,232	11,248		4,288		15,628	22,013		8,183	
Hospital Payor Mix	,		,	,		,	,			
Medicare	47.8%	48.0%	48.4%	(0.4%)		48.6%	47.6%	48.4%	(0.8%	
Medi-Cal	8.1%	6.9%		(0.5%)		7.9%	7.1%		(0.3%	
Commercial IP	20.1%	20.4%		(0.3%)		19.7%	20.7%		0.19	
Commercial OP	22.5%	21.7%		0.6%		21.7%	20.7%		1.09	
Total Commercial	42.6%	42.1%		0.3%	ŀ	41.4%	42.9%		1.19	
Other	1.6%	3.0%		0.6%		2.1%	2.4%		(0.0%	
Hospital Cost	2.070	3.070	2.370	0.070		2.1270	2.170	2.370	(0.070	
-	0.707.4		2.002.4	70.4		0.740.7	2 74 2 2	20110		
Total FTE ¹ Productive Hrs/APD	2,737.1 31.6	2,749.7 31.1		72.4 4.8		2,743.7 31.4	2,719.8 31.1		91.2 5.1	
Consolidated Balance Sheet	52.0	01.1	- 55.5			52.4	31.1	30.2	3.1	
Net Days in AR	48.6	50.0	49.0	(1.0)		48.6	50.0	49.0	(1.0	
Net Days In AR Days Cash	48.6 469	50.0		(1.0) 92		48.6	50.0		(1.0 92	
Days CdSII	409	528	435	92	<u> </u>	409	328	433	92	



 $^{^{\}mathbf{1}}$ Paid FTE; Budget in this case is using the Flex Budget instead of Fixed Budget





APPENDIX



August Volume – Inpatient 2021 Budget vs Actual – Including Pre COVID Level


MV







August Volume – Outpatient 2021 Budget vs Actual – Including Pre COVID Level







Investment Scorecard as of June 30, 2020

Key Performance Indicator	Status	El Camino	Benchmark	El Camino	Benchmark	El Camino	Benchmark	FY20 Budget	Expectation Pe
									Asset Allocatio
Investment Performance		2Q 2020		Fiscal Year-to-date		7y 8m Since Inception (annualized)		FY 2020	2019
Surplus cash balance*		\$1,076.6	-	-		-		-	-
Surplus cash return		10.2%	9.7%	3.6%	4.0%	5.4%	5.3%	4.0%	5.6%
Cash balance plan balance (millions)		\$286.7	-	-		-		-	-
Cash balance plan return		13.2%	11.3%	3.8%	3.7%	7.3%	6.6%	6.0%	6.0%
403(b) plan balance (millions)		\$551.4	-						
Risk vs. Return		3-year					e Inception alized)		2019
Surplus cash Sharpe ratio		0.47	0.46			0.78	0.78		0.34
Net of fee return		5.3%	5.2%	-		5.4%	5.3%		5.6%
Standard deviation		7.9%	7.6%			5.9%	5.8%		8.7%
Cash balance Sharpe ratio		0.48	0.45			0.85	0.83	-	0.32
Net of fee return		6.3%	5.6%	-		7.3%	6.6%	-	6.0%
Standard deviation		10.0%	9.1%			7.6%	7.1%		10.3%
Asset Allocation		2Q	2020						
Surplus cash absolute variances to target		12.5%	< 10% Green < 20% Yellow			-		-	
Cash balance absolute variances to target		11.7%	< 10% Green < 20% Yellow	-		-	-	-	-
Manager Compliance	2Q	2020							
Surplus cash manager flags		18	< 24 Green < 30 Yellow			-		-	
Cash balance plan manager flags		21	< 27 Green < 34 Yellow			-		-	

^{*}Excludes debt reserve funds (~\$21 mm), District assets (~\$42 mm), and balance sheet cash not in investable portfolio (\$234 mm). Includes Foundation (~\$36 mm) and Concern (~\$14 mm) assets.



© 2020 Mercer LLC. All rights reserved.

